Abstract

BackgroundWe have previously found that TLR4-deficient (TLR4-/-) mice demonstrate decreased expression of mucosal PGE 2 and are protected against colitis-associated neoplasia. However, it is still unclear whether PGE 2 is the central factor downstream of TLR4 signaling that promotes intestinal tumorigenesis. To further elucidate critical downstream pathways involving TLR4-mediated intestinal tumorigenesis, we examined the effects of exogenously administered PGE 2 in TLR4-/- mice to see if PGE 2 bypasses the protection from colitis-associated tumorigenesis.MethodMouse colitis-associated neoplasia was induced by azoxymethane (AOM) injection followed by two cycles of dextran sodium sulfate (DSS) treatment. Two different doses of PGE 2 (high dose group, 200 μg, n = 8; and low dose group, 100 μg, n = 6) were administered daily during recovery period of colitis by gavage feeding. Another group was given PGE 2 during DSS treatment (200 μg, n = 5). Inflammation and dysplasia were assessed histologically. Mucosal Cox-2 and amphiregulin (AR) expression, prostanoid synthesis, and EGFR activation were analyzed.ResultsIn control mice treated with PBS, the average number of tumors was greater in WT mice (n = 13) than in TLR4-/- mice (n = 7). High dose but not low dose PGE 2 treatment caused an increase in epithelial proliferation. 28.6% of PBS-treated TLR4-/- mice developed dysplasia (tumors/animal: 0.4 ± 0.2). By contrast, 75.0% (tumors/animal: 1.5 ± 1.2, P < 0.05) of the high dose group and 33.3% (tumors/animal: 0.3 ± 0.5) of the low dose group developed dysplasia in TLR4-/- mice. Tumor size was also increased by high dose PGE 2 treatment. Endogenous prostanoid synthesis was differentially affected by PGE 2 treatment during acute and recovery phases of colitis. Exogenous administration of PGE 2 increased colitis-associated tumorigenesis but this only occurred during the recovery phase. Lastly, PGE 2 treatment increased mucosal expression of AR and Cox-2, thus inducing EGFR activation and forming a positive feedback mechanism to amplify mucosal Cox-2.ConclusionsThese results highlight the importance of PGE 2 as a central downstream molecule involving TLR4-mediated intestinal tumorigenesis.

Highlights

  • We have previously found that TLR4-deficient (TLR4-/-) mice demonstrate decreased expression of mucosal prostaglandin E 2 (PGE 2) and are protected against colitis-associated neoplasia

  • PGE 2 treatment increased mucosal expression of AR and cyclooxygenase 2 (Cox-2), inducing epidermal growth factor receptor (EGFR) activation and forming a positive feedback mechanism to amplify mucosal Cox-2. These results highlight the importance of PGE 2 as a central downstream molecule involving TLR4mediated intestinal tumorigenesis

  • Oral PGE 2 supplementation promotes development of colitis-associated colorectal neoplasia in TLR4-/- mice We have demonstrated that TLR4-/- mice are protected against development of colitis-associated neoplasia in the AOM-dextran sodium sulfate (DSS) model [28]

Read more

Summary

Introduction

We have previously found that TLR4-deficient (TLR4-/-) mice demonstrate decreased expression of mucosal PGE 2 and are protected against colitis-associated neoplasia. It is still unclear whether PGE 2 is the central factor downstream of TLR4 signaling that promotes intestinal tumorigenesis. Patients with ulcerative colitis (UC) are at increased risk of developing colorectal cancer. The colorectal cancer development in UC patients is identified as colitis-associated cancer (CAC). The increased incidence of colorectal cancer in patients with UC highlights the well-known link between chronic inflammation and carcinogenesis [3]. Understanding the mechanisms underlying inflammation-induced colorectal cancer will aid in establishing new strategies for prevention and/or treatment of CAC

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call